BONE: EVIDENCE AND UNKNOWNS
Retatrutide and bone health: what is actually known
The honest summary is short: no published retatrutide study has reported bone mineral density, bone-turnover markers or fracture outcomes. What exists is a wider weight-loss and incretin literature that makes bone a legitimate research question — and a clear statement of what RetaBone does not claim.
The RetaBone name does not mean that the formulation has been demonstrated to increase bone density, prevent fractures or preserve skeletal muscle. These remain separate scientific questions requiring dedicated study.
What is known
Major weight loss can influence mechanical loading and body composition — and bone is a mechanical organ. When the load it carries changes, bone remodelling is a reasonable thing to monitor. The narrative review by Stefanakis and colleagues (Metabolism 2024) ↗ places bone alongside muscle and hematopoietic health in the fat-free-mass story: more than 25% of weight lost with surgery or incretin pharmacotherapy typically comes from fat-free mass, and emerging pharmacotherapies are being designed around that fact. What it supports: bone belongs in the body-composition research frame. What it does not prove: long-term fracture or functional outcomes of incretin-associated bone effects remain unestablished — and the review is narrative, not primary data.
In the Lundgren weight-maintenance trial ↗, combined exercise plus liraglutide outperformed either alone for maintenance and body-fat-percentage reduction; bone mineral density appeared only in secondary analyses, not as a primary endpoint. Exercise is the intervention with the most direct mechanical-loading rationale for bone — which is one reason RetaBone treats resistance training as non-negotiable context, never as an optional extra.
What is unknown
Evidence regarding individual incretin therapies and bone outcomes remains developing. Molecule-specific, dose-specific and population-specific bone data for retatrutide do not exist in the published record as of the last evidence search. Nothing in the retatrutide DXA substudy, TRANSCEND-T2D-1 or the phase 2 trials measured bone.
Rethiamine has not been demonstrated to preserve bone mineral density. Appropriate research would require DXA, bone-turnover markers and controlled longitudinal evaluation. Until such data exist, every bone statement on this site is a statement about the literature and the research agenda — not about the formulation.
Thiamine is not a bone-building medicine, and this site never presents it as one. The thiamine research question is about energy metabolism and nervous-system function, and the nutritional-resilience frame is described under rapid weight loss and nutritional vulnerability.